Business
The ASX healthcare shares Goldman Sachs rates as a buy
Goldman Sachs hosted its 4th small/mid-cap healthcare forum this week. This included 13 Australian and New Zealand healthcare companies across a diverse range of specialties. Here are the ASX healthcare shares that Goldman picked as a buy.
Goldman’s ASX healthcare shares to buy
Opthea Ltd (ASX: OPT)
Opthea is developing a complementary medicine to be used with existing inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Goldman believes there is multi-billion dollar potential in Opthea’s treatment. The broker observes that existing treatments only inhibit up to two of the factors responsible for retinal disease, with over half of patients not achieving…
-
General22 hours agoMan arrested after alleged carjackings, dramatic pursuit in Melbourne CBD
-
Noosa News24 hours ago‘Stolen’ Skoda speeds near Dreamworld with police helicopter watching
-
Noosa News13 hours agoAllegedly armed man who sparked hours-long lockdown of Brisbane City Botanic Gardens in custody
-
Business24 hours agoBuy these ASX dividend shares for 4% to 6% yields